758
Views
70
CrossRef citations to date
0
Altmetric
Original Articles

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study

, Ph.D., , , Ph.D., , , M.P.H., , , Ph.D., , Ph.D., , M.A., M.F.T., , B.A., , M.D., , M.A. & , M.D. show all

REFERENCES

  • Al-Tayyib, A.A. & Koester, S. 2011. Injection drug users’ experience with and attitudes toward methadone clinics in Denver, CO. Journal of Substance Abuse Treatment 41 (1): 30–6.
  • Awgu, E.; Magura, S. & Rosenblum, A. 2010. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. Journal of Psychoactive Drugs 42 (3): 339–46.
  • Ball, J.C. & Ross, A. 1991. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. New York: Springer-Verlag.
  • Barry, D.T.; Irwin, K.S.; Jones, E.S.; Becker, W.C.; Tetrault, J.M.; Sullivan, L.E.; Hansen, H.; O’Connor, P.G.; Schottenfeld, R.S. & Fiellin, D.A. 2009. Integrating buprenorphine treatment into office-based practice: A qualitative study. Journal of General Internal Medicine 24 (2): 218–25.
  • Bazazi, A.R.; Yokell, M.; Fu, J.J.; Rich, J.D. & Zaller, N.D. 2011. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine 5 (3): 175–80.
  • Bechtel, C. & Ness, D.L. 2010. If you build it, will they come? Designing truly patient-centered health care. Health Affairs 29 (5): 914–20.
  • Bell, J.; Trinh, L.; Butler, B.; Randall, D. & Rubin, G. 2009. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 104 (7): 1193–200.
  • Binswanger, I.A.; Stern, M.F.; Deyo, R.A.; Heagerty, P.J.; Cheadle, A.; Elmore, J.G. & Koepsell, T.D. 2007. Release from prison: A high risk of death for former inmates. New England Journal of Medicine 356 (2): 157–65.
  • Booth, R.E.; Corsi, K.F. & Mikulich-Gilbertson, S.K. 2004. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug and Alcohol Dependence 74 (2): 177–85.
  • Boyatzis, R.E. 1998. Thematic Analysis and Code Development: Transforming Qualitative Information. Thousand Oaks, CA: Sage.
  • Caplehorn, J.R.; Dalton, M.S.; Haldar, F.; Petrenas, A.M. & Nisbet, J.G. 1996. Methadone maintenance and addicts’ risk of fatal heroin overdose. Substanc Use and Misuse 31 (2): 177–196.
  • Center for Substance Abuse Treatment. 2004. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  • Connock, M.; Juarez-Garcia, A.; Jowett, S.; Frew, E.; Liu, Z.; Taylor, R.J.; Fry-Smith, A.; Day, E.; Lintzeris, N.; Roberts, T.; Burls, A. & Taylor, R.S. 2007. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment 11 (9): 1–171, iii–iv.
  • Coviello, D.M.; Zanis, D.A.; Wesnoski, S.A. & Alterman, A.I. 2006. The effectiveness of outreach case management in re-enrolling discharged methadone patients. Drug and Alcohol Dependence 85 (1): 56–65.
  • Creswell, J.W. 2003. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, 2nd ed. Thousand Oaks, CA: Sage.
  • Deck, D. & Carlson, M.J. 2005. Retention in publicly funded methadone maintenance treatment in two Western States. Journal of Behavioral Health Services and Research 32 (1): 43–60.
  • Demetrovics, Z.; Farkas, J.; Csorba, J.; Nemeth, A.; Mervo, B.; Szemelyacz, J.; Fleischmann, E.; Kassai-Farkas, A.; Petke, Z.; Orojan, T.; Rozsa, S.; Rigo, P.; Funk, S.; Kapitany, M.; Kollar, A. & Racz, J. 2009. Early experience with Suboxone maintenance therapy in Hungary. Neuropsychopharmacologia Hungarica 11 (4): 249–57.
  • Ducharme, L.J. & Abraham, A.J. 2008. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment Prevention Policy 3: 17.
  • Egan, J.E.; Netherland, J.; Gass, J.; Finkelstein, R.; Weiss, L. & Collaborative, B. 2011. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. Journal of Acquired Immune Deficiency Syndromes 56 Suppl 1: S46–53.
  • Fareed, A.; Vayalapalli, S.; Casarella, J. & Drexler, K. 2012. Treatment outcome for flexible dosing buprenorphine maintenance treatment. American Journal of Drug and Alcohol Abuse 38 (2): 155–60.
  • Fischer, G.; Gombas, W.; Eder, H.; Jagsch, R.; Peternell, A.; Stuhlinger, G.; Pezawas, L.; Aschauer, H.N. & Kasper, S. 1999. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94 (9): 1337–47.
  • Friedman, H.; Newton, C. & Klein, T.W. 2003. Microbial infections, immunomodulation, and drugs of abuse. Clinical Microbiology Reviews 16 (2): 209–19.
  • Fudala, P.J.; Bridge, T.P.; Herbert, S.; Williford, W.O.; Chiang, C.N.; Jones, K.; Collins, J.; Raisch, D.; Casadonte, P.; Goldsmith, R.J.; Ling, W.; Malkerneker, U.; McNicholas, L.; Renner, J.; Stine, S.; Tusel, D. & Group., B.N.C.S. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349 (10): 949–58.
  • Glaser, B.G. & Strauss, A.L. 1967. The Discovery of Grounded Theory. New York: Aldine de Gruyter.
  • Gossop, M.; Marsden, J.; Stewart, D. & Kidd, T. 2003. Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up. Addictive Behaviors 28 (4): 785–93.
  • Hser, Y.; Joshi, V.; Maglione, M.; Chou, C. & Anglin, D. 2001. Effects of program and patient characteristics on retention of drug treatment patients. Evaluation and Program Planning 24: 331–341.
  • Hser, Y.I. 2007. Predicting long-term stable recovery from heroin addiction: Findings from a 33-year follow-up study. Journal of Addictive Diseases 26 (1): 51–60.
  • Hubbard, R.L.; Craddock, S.G.; Flynn, P.M.; Anderson, J. & Etheridge, R.M. 1997. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors 11 (4): 261–278.
  • Hubbard, R.L., Craddock, S. G.,Anderson, J. 2003. Overview of 5-year follow-up outcomes in the Drug Abuse Treatment Outcome Studies (DATOS). Journal of Substance Abuse Treatment 25 (3): 125–134.
  • Huberman, A.M. & Miles, M.B. 1994. Data management and analysis methods. In: N. K. Denzin & Y. S. Lincoln ( Eds.) Handbook of Qualitative Research. Thousand Oaks, CA: Sage.
  • Institute of Medicine. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press.
  • Joe, G.W.; Simpson, D.D. & Broome, K.M. 1998. Effects of readiness for drug abuse tratment on client retention and assessment of process. Addiction 93 (8): 1177–90.
  • Johnson, R.E.; Chutuape, M.A.; Strain, E.C.; Walsh, S.L.; Stitzer, M.L. & Bigelow, G.E. 2000. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343 (18): 1290–7.
  • Johnson, R.E. & McCagh, J.C. 2000. Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports 2 (6): 519–26.
  • Jones, H.E. 2004. Practical considerations for the clinical use of buprenorphine. Science & Practice Perspectives 2 (2): 4–20.
  • Kamien, J.B.; Branstetter, S.A. & Amass, L. 2008. Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients Heroin Addiction and Related Clinical Problems 10 (4): 5–8.
  • Kelly, S.M.; O’Grady, K.E.; Mitchell, S.G.; Brown, B.S. & Schwartz, R.P. 2011. Predictors of methadone treatment retention from a multi-site study: A survival analysis. Drug and Alcohol Dependence 117 (2–3): 170–5.
  • Kimber, J.; Copeland, L.; Hickman, M.; Macleod, J.; McKenzie, J.; De Angelis, D. & Robertson, J.R. 2010. Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment. British Medical Journal 341: c3172.
  • Koester, S.; Anderson, K. & Hoffer, L. 1999. Active heroin injectors’ perceptions and use of methadone maintenance treatment: Cynical performance or self-prescribed risk reduction? Substance Use and Misuse 34 (14): 2135–53.
  • Kosten, T.R. 1994. Buprenorphine for benzodiazepine-abusing heroin addicts. American Journal of Psychiatry 151 (1): 151.
  • Kristensen, O.; Espegren, O.; Asland, R.; Jakobsen, E.; Lie, O. & Seiler, S. 2005. Buprenorphine and methadone to opiate addicts: A randomized trial. Tidsskrift for den Norske Laegeforening 125 (2): 148–51.
  • Ling, W.; Charuvastra, C.; Collins, J.F.; Batki, S.; Brown, L.S. Jr.; Kintaudi, P.; Wesson, D.R.; McNicholas, L.; Tusel, D.J.; Malkerneker, U.; Renner, J.A. Jr.; Santos, E.; Casadonte, P.; Fye, C.; Stine, S.; Wang, R.I. & Segal, D. 1998. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93 (4): 475–86.
  • Ling, W.; Wesson, D.R.; Charuvastra, C. & Klett, C.J. 1996. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 53 (5): 401–7.
  • Magura, S.; Nwakeze, P.C. & Demsky, S.Y. 1998. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 93 (1): 51–60.
  • Mattick, R.P.; Ali, R.; White, J.M.; O’Brien, S.; Wolk, S. & Danz, C. 2003. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98 (4): 441–52.
  • Mattick, R.P.; Kimber, J.; Breen, C. & Davoli, M. 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (2): CD002207.
  • Metzger, D.S.; Woody, G.E.; McLellan, A.T.; O’Brien, C.P.; Druley, P.; Navaline, H.; DePhilippis, D.; Stolley, P. & Abrutyn, E. 1993. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes 6 (9): 1049–1056.
  • Mitchell, S.G.; Gryczynski, J.; Schwartz, R.P.; O’Grady, K.E.; Olsen, Y.K. & Jaffe, J.H. 2012. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug and Alcohol Dependence 128 (3): 222–29.
  • Mitchell, S.G.; Kelly, S.M.; Brown, B.S.; Reisinger, H.S.; Peterson, J.A.; Ruhf, A.; Agar, M.H. & Schwartz, R.P. 2009. Incarceration and opioid withdrawal: The experiences of methadone patients and out-of-treatment heroin users. Journal of Psychoactive Drugs 41 (2): 145–52.
  • Patton, M.Q. 1990. Qualitative Research and Evaluation Methods. Newbury Park, CA: Sage.
  • Ponizovsky, A.M. & Grinshpoon, A. 2007. Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse 33 (5): 631–42.
  • Reisinger, H.S.; Schwartz, R.P.; Mitchell, S.G.; Peterson, J.A.; Kelly, S.M.; O’Grady, K.E.; Marrari, E.A.; Brown, B.S. & Agar, M.H. 2009. Premature discharge from methadone treatment: Patient perspectives. Journal of Psychoactive Drugs 41 (3): 285–96.
  • Rhoades, H.M.; Creson, D.; Elk, R.; Schmitz, J. & Grabowski, J. 1998. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health 88 (1): 34–9.
  • Ronald, P.J.; Robertson, J.R. & Elton, R.A. 1994. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 8 (3): 339–43.
  • Saxon, A.J.; Ling, W.; Hillhouse, M.; Thomas, C.; Hasson, A.; Ang, A.; Doraimani, G.; Tasissa, G.; Lokhnygina, Y.; Leimberger, J.; Bruce, R.D.; McCarthy, J.; Wiest, K.; McLaughlin, P.; Bilangi, R.; Cohen, A.; Woody, G. & Jacobs, P. 2013. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence 128 (1–2): 71–6.
  • Saxon, A.J.; Wells, E.A.; Fleming, C.; Jackson, T.R. & Calsyn, D.A. 1996. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 91 (8): 1197–209.
  • Schottenfeld, R.S.; Pakes, J.R.; Oliveto, A.; Ziedonis, D. & Kosten, T.R. 1997. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry 54 (8): 713–20.
  • Schwartz, R.P.; Kelly, S.M.; O’Grady, K.E.; Mitchell, S.G.; Peterson, J.A.; Reisinger, H.S.; Agar, M.H. & Brown, B.S. 2008. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. American Journal on Addictions 17 (5): 396–401.
  • Simpson, D.D. 1981. Treatment for drug abuse: Follow-up outcomes and length of time spent. Archives of General Psychiatry 38 (8): 875–80.
  • Simpson, D.D.; Joe, G.W.; Rowan-Szal, G.A. & Greener, J.M. 1997. Drug abuse treatment process components that improve retention. Journal of Substance Abuse Treatment 14 (6): 565–72.
  • Skinner, M.L.; Haggerty, K.P.; Fleming, C.B.; Catalano, R.F. & Gainey, R.R. 2011. Opiate-addicted parents in methadone treatment: Long-term recovery, health, and family relationships. Journal of Addictive Diseases 30 (1): 17–26.
  • Soyka, M.; Zingg, C.; Koller, G. & Kuefner, H. 2008. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology 11 (5): 641–53.
  • Specter, S. 1994. Drugs of abuse and infectious diseases. Journal of the Florida Medical Association 81 (7): 485–7.
  • Strain, E.C.; Stitzer, M.L.; Liebson, I.A. & Bigelow, G.E. 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 151 (7): 1025–30.
  • Strain, E.C.; Stitzer, M.L.; Liebson, I.A. & Bigelow, G.E. 1996. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. Journal of Clinical Psychopharmacology 16 (1): 58–67.
  • Teesson, M.; Mills, K.; Ross, J.; Darke, S.; Williamson, A. & Havard, A. 2008. The impact of treatment on 3 years’ outcome for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 103 (1): 80–8.
  • United States Department of Health and Human Services 2012. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction: Proposed Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combination as Used in Approved Opioid Treatment Medications. Washington, DC: Substance Abuse and Mental Health Services Administration.
  • Wallen, M.C.; Lorman, W.J. & Gosciniak, J.L. 2006. Combined buprenorphine and chlonidine for short-term opiate detoxification: Patient perspectives. Journal of Addictive Diseases 25 (1): 23–31.
  • Winstock, A.R.; Lintzeris, N. & Lea, T. 2011. “Should I stay or should I go?” Coming off methadone and buprenorphine treatment. International Journal of Drug Policy 22 (1): 77–81.
  • Xiao, L.; Wu, Z.; Luo, W. & Wei, X. 2010. Quality of life of outpatients in methadone maintenance treatment clinics. Journal of Acquired Immune Deficiency Syndromes 53 Suppl 1: S116–20.
  • Zhang, Z.; Friedmann, P.D. & Gerstein, D.R. 2003. Does retention matter? Treatment duration and improvement in drug use. Addiction 98: 673–684.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.